NEW YORK, January 12, 2017 /PRNewswire/ --
Biotechnology was one of the weakest performing sectors in 2016, declining over -21%, as represented by the iShares Nasdaq Biotechnology ETF. According to an article on Seeking Alpha, signs of a potential breakout for the industry this year are present and M&As are expected to catalyze momentum and improve investor confidence. Ahead of today's trading session, Stock-Callers.com tracks the performances of the following equities: Halozyme Therapeutics Inc. (NASDAQ: HALO), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Curis Inc. (NASDAQ: CRIS), and Agios Pharmaceuticals Inc. (NASDAQ: AGIO). Download the free research reports on these stocks today:
On Wednesday, shares in California headquartered Halozyme Therapeutics Inc. recorded a trading volume of 2.93 million shares, which was above their three months average volume of 2.07 million shares. The stock ended the day at $11.91, dropping 7.60% from the last trading session. The Company's shares have advanced 3.30% in the last one month, 2.85% over the previous three months, and 20.55% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 5.53% and 14.68%, respectively. Furthermore, shares of Halozyme Therapeutics, which researches, develops, and commercializes human enzymes, have a Relative Strength Index (RSI) of 52.16.
On January 06th, 2017, research firm Citigroup downgraded the Company's stock rating from 'Buy' to 'Neutral'.
On January 09th, 2017, Halozyme Therapeutics announced that two new studies exploring four tumor types are planned to start in 2017 as part of a recently announced clinical collaboration with Genentech. Halozyme has also been included in an innovative, patient-centered clinical trial planned for initiation in 2017 called Precision Promise, led by the Pancreatic Cancer Action Network. The Company also provided financial guidance for 2017 of revenue of $115 million to $130 million, excluding revenue from any new ENHANZE global collaboration and licensing agreements that may be signed during the year. Operating expenses is expected to be between $240 million to $250 million and year-end cash balance in range of $100 million to $110 million. See our free and comprehensive research report on HALO at:
Massachusetts headquartered Keryx Biopharmaceuticals Inc.'s stock rose 3.23%, finishing yesterday's session at $6.40. A total volume of 3.30 million shares was traded, which was above their three months average volume of 1.49 million shares. The Company's shares have gained 6.49% in the last month, 18.08% in the previous three months, and 9.22% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 11.71% and 16.55%, respectively. Additionally, shares of Keryx Biopharma, which focuses on providing therapies for patients with renal disease in the US, have an RSI of 62.19.
On January 08th, 2017, Keryx Biopharmaceuticals announced that it has appointed Christine Carberry as Chief Operating Officer and Melissa Bradford-Klug as Chief Business Officer, both will report to Greg Madison. Ms. Carberry will start on January 16th, 2017, while Ms. Bradford-Klug started on January 03rd, 2017.
Yesterday, research firm Citigroup upgraded the Company's stock rating from 'Sell' to 'Neutral'. KERX free research report PDF is just a click away at:
Shares in Massachusetts headquartered Curis Inc. ended Wednesday's session 3.83% lower at $3.01. The stock recorded a trading volume of 755,410 shares, which was above its three months average volume of 622,650 shares. The Company's shares have gained 3.44% in the last one month. The stock is trading 35.44% above its 200-day moving average. Moreover, shares of Curis, which engages in the discovery and development of drug candidates for the treatment of human cancers, have an RSI of 45.08.
On January 09th, 2017, Curis announced that it has exercised its option to extend the exclusivity period with Aurigene under the collaboration, license and option agreement established in January, 2015. The extension of exclusivity is associated with a payment of $7.5 million to Aurigene, payable in two equal installments in the Q1 and Q3 of 2017. Sign up for your complimentary report on CRIS at:
At the close, Massachusetts-based Agios Pharmaceuticals Inc.'s stock slid 4.02%, finishing at $40.56. A total volume of 921,419 shares was traded, which was above their three months average volume of 847,000 shares. The Company's shares are trading 15.82% below their 200-day moving average. Additionally, shares of Agios Pharma, which engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the US, have an RSI of 35.47.
On January 08th, 2017, Agios Pharma announced that it expects to achieve potential approval of enasidenib in the US for IDH2m positive R/R AML in collaboration with Celgene by the end of 2017. The company plans to submit a new drug application to the US FDA for AG-120 by the end of 2017. Register for free on Stock-Callers.com and download the latest research report on AGIO at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA